Vic has worked in market access roles for nearly 15 years, starting her career at a specialist market access consultancy before moving to a pharmaceutical company and then the ABPI. At the ABPI, Vic leads on policy related to HTA and market access more broadly, spanning from horizon scanning through to medicines evaluation and adoption of medicines in the NHS. She takes a collaborative approach to finding solutions for improving patient access to innovative medicines, working with industry, government, system partners, patient groups and academics.

Over the last seven years, Vic’s work at the ABPI has helped evolve medicines value and access policy in the UK, including chapter 3 of the 2019 and 2024 voluntary schemes, NICE’s manual for health technology evaluation and the Competition and Markets Authority’s prioritisation statement for combination therapies.

Vic has a masters in economic evaluation for HTA, health economics from the University of York and enjoys bringing together advances in medicines evaluation methods and processes with the practicalities of getting new medicines to patients in the NHS.